PM
ANAB icon

Prosight Management’s AnaptysBio ANAB Stock Holding History

Prosight Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-78,976
Closed -$1.12M – 54
2020
Q1 		$1.12M Sell
78,976
-155,847
-66% -$2.36M 0.52% 33
2019
Q4 		$3.82M Buy
+234,823
New +$5.55M 1.68% 19

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Prosight Management's ANAB Position: Q2 2020 in Review

Prosight Management sold out of AnaptysBio (ANAB) in Q2 2020, closing a stake of 78,976 shares — an estimated $1.12M sold.

Prosight Management first reported a position in ANAB in Q4 2019 and held it in 2 quarters. The position peaked at $3.82M in Q4 2019. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2020.

  • Prosight Management reported no remaining AnaptysBio position as of Q2 2020 after selling out during the quarter.
  • Prosight Management sold 78,976 AnaptysBio shares in Q2 2020, an estimated $1.12M.
  • Prosight Management first reported a position in AnaptysBio in Q4 2019 and held it in 2 quarters.
  • Prosight Management's AnaptysBio position peaked at $3.82M in Q4 2019.
  • 122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2020.

Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.